PMID- 32494237
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1617-9625 (Electronic)
IS  - 2070-7266 (Print)
IS  - 1617-9625 (Linking)
VI  - 18
DP  - 2020
TI  - Safety of varenicline as an aid to smoking cessation in professional drivers and 
      its impact on driving behaviors: An observational cohort study of taxi drivers in 
      Beijing.
PG  - 45
LID - 10.18332/tid/120935 [doi]
LID - 45
AB  - INTRODUCTION: Varenicline is an effective smoking cessation medicine. However, 
      the possible adverse neuropsychiatric events reported by Food and Drug 
      Administration for varenicline may cause safety problems for professional 
      drivers. We aimed to investigate its safety and impacts on driving behaviors 
      among taxi drivers in Beijing, China. METHODS: An observational cohort study was 
      conducted in a smoking cessation clinic in Beijing, China, between September 2017 
      and April 2018. Smokers with varenicline for smoking cessation were included and 
      categorized into taxi-driver smokers (n=103) and non-taxi-driver smokers (n=119). 
      All participants received varenicline up to 12 weeks and five standardized 
      counseling sessions. Treatment-related adverse events (AEs) were collected in all 
      participants and their impacts on driving behaviors were assessed in taxi-driver 
      smokers. Multiple logistic regression analysis was used to examine potential risk 
      factors for vareniclinerelated somnolence/fatigue. RESULTS: The incidence of most 
      treatment-related AEs was similar between taxi-driver smokers and non-taxi-driver 
      smokers, but treatment-related somnolence/ fatigue was more frequently reported 
      in taxi-driver smokers (18.4% vs 6.7%; p=0.008). Most taxi-driver smokers (87.4%) 
      reported that treatment-related AEs did not affect their driving behaviors, and 
      no traffic accident was reported during treatment. CONCLUSIONS: Varenicline 
      appears to be a well-tolerated smoking cessation aid for Beijing taxi drivers and 
      has less impact on driving behaviors. However, taxi-driver smokers were more 
      likely to report somnolence/fatigue during varenicline treatment and physicians 
      should pay more attention to this occupational population.
CI  - (c) 2020 Chu S. et al.
FAU - Chu, Shuilian
AU  - Chu S
AD  - Department of Clinical Epidemiology and Tobacco Dependence Treatment Research, 
      Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
AD  - Beijing Institute of Respiratory Medicine, Beijing, China.
FAU - Liang, Lirong
AU  - Liang L
AD  - Department of Clinical Epidemiology and Tobacco Dependence Treatment Research, 
      Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
AD  - Beijing Institute of Respiratory Medicine, Beijing, China.
FAU - Jing, Hang
AU  - Jing H
AD  - Department of Clinical Epidemiology and Tobacco Dependence Treatment Research, 
      Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
AD  - Beijing Institute of Respiratory Medicine, Beijing, China.
FAU - Zhang, Di
AU  - Zhang D
AD  - Department of Clinical Epidemiology and Tobacco Dependence Treatment Research, 
      Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
AD  - Beijing Institute of Respiratory Medicine, Beijing, China.
FAU - Tong, Zhaohui
AU  - Tong Z
AD  - Beijing Institute of Respiratory Medicine, Beijing, China.
AD  - Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, 
      Capital Medical University, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - Greece
TA  - Tob Induc Dis
JT  - Tobacco induced diseases
JID - 101201591
PMC - PMC7263361
OTO - NOTNLM
OT  - driving behaviors
OT  - safety
OT  - smoking cessation
OT  - taxi drivers
OT  - varenicline
COIS- The authors have completed and submitted the ICMJE Form for Disclosure of 
      Potential Conflicts of Interest and none was reported.
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:01
PMCR- 2020/05/27
CRDT- 2020/06/05 06:00
PHST- 2019/11/10 00:00 [received]
PHST- 2020/03/10 00:00 [revised]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:01 [medline]
PHST- 2020/05/27 00:00 [pmc-release]
AID - 45 [pii]
AID - 10.18332/tid/120935 [doi]
PST - epublish
SO  - Tob Induc Dis. 2020 May 27;18:45. doi: 10.18332/tid/120935. eCollection 2020.